Prostate cancer tumors contain twice as much microplastic as healthy tissue

Researchers at NYU Langone Health have found something unsettling in the tissue samples of prostate cancer patients: plastic. Not much of it in any single location, but enough to raise a question that has haunted public health officials and environmental scientists for years—what is plastic actually doing inside our bodies, and could it be making us sick?

The study examined cancerous and benign prostate tissue from ten patients with prostate cancer, the most frequently diagnosed cancer among American men. In nine of those ten cases, the researchers discovered microscopic plastic fragments in both the healthy tissue and the tumors. The difference was striking. The cancerous tissue contained roughly 40 micrograms of plastic per gram, while the healthy samples held about 16 micrograms per gram. The tumors, in other words, contained more than twice as much plastic.

To find these particles, the team used specialized equipment made from non-plastic materials to avoid contamination of their own samples. They searched for molecules from twelve of the most common plastics—the ones that break down from packaging on food, personal care products, and countless other consumer goods. Microplastics have become inescapable. They fragment from products we use daily, enter our bodies through ingestion and inhalation, and have been detected in virtually every human organ, in blood, in lung tissue, even in placentas. No living thing appears to be spared.

Vittorio Albergamo, an assistant professor at NYU Grossman School of Medicine and senior author of the study, framed the findings as a call to action. The accumulating evidence of plastic's presence in human tissue, he said, demands stricter regulations on manufacturers whose products are degrading into particles that end up everywhere in the environment and inside us. Stacy Loeb, another lead researcher and a professor in the departments of urology and population health, noted that this represents the first study in the United States to directly connect microplastic exposure to prostate cancer specifically, and the first Western assessment to compare plastic levels between cancerous and noncancerous prostate tissue.

The stakes are substantial. The CDC estimates that one in eight American men will develop prostate cancer at some point in their lives. Yet the mechanisms by which plastic might contribute to that risk remain largely unknown. Researchers still cannot say with certainty how microplastics interact with human biology or what cascade of events might lead from exposure to disease. Albergamo's team has a working hypothesis: that microplastics could trigger an overactive immune response in tissue, causing chronic inflammation that over time damages cells and triggers the genetic changes that spawn cancer. Testing that theory, however, will require a much larger sample size and further investigation.

For now, the study stands as evidence that plastic is not simply an environmental problem or a matter of waste management. It is present in the bodies of cancer patients at concentrations that dwarf what appears in healthy tissue from the same individuals. Whether that presence is a cause, a consequence, or simply a marker of broader exposure remains to be determined. But the question itself—what is plastic doing to us—has moved from speculation into the realm of measurable biological fact.